Former FDA leaders, pharma speak out on mifepristone

The Supreme Court is expected to make a decision on the abortion medication mifepristone, which could impact the regulatory authority of the Food and Drug Administration. The case involves a federal appeals court decision to stop mail orders of the medication. The outcome could affect abortion providers and patients.